The latest biotech news - Labiotech.eu

Home News and Trends Page 357

Latest Posts

News and Trends 29 Aug 2015

Cambridge’s Algal Innovation Center is soon finished!

The European Energetic Algae project explores the potential of algae as an energy source. Its half a million euros Algal Innovation Center in Cambridge will soon scale up the research. The Energetic Algae project, shortly EnAlgae, aims to reduce our reliance on fossil fuels by developing biofuel technologies based on algae. “A lot of people don’t realize […]

August 29, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 28 Aug 2015

[Update] Valneva’s duck stem cells attract two new Vaccine-deals

French Valneva continues to sign license agreements for its duck derived stem cell line that produces novel vaccines. Lyon-based Valneva was formed from the 70-year old duck breeder Group Grimaud. It entered the biotech scene in 2000 as Vivalis and today is on Euronext-Paris and the Vienna stock exchange, has a market cap of about €275M […]

August 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 28 Aug 2015

FDA shelves UniQure’s Glybera – will the Gene therapy once reach the US market?

The €1.1M drug Glybera was the first gene therapy on the European market. UniQure wants to sell it in the US too, but the FDA makes it much more difficult than expected. UniQure’s financial report of the first half of 2015 shows good results, cash and cash equivalents of the company increased to €181.9M, compared with […]

August 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Aug 2015

Dutch Immuno-Oncology company raises Massive Series C Financing round

Sofinnova Ventures and Novo A/S step into one of the biggest European series C financing rounds, which is about €72.8 million. The money goes to the Dutch immuno-oncology company Merus and will advance its cancer-fighting bispecific antibodies. Back in April, Merus announced its intention to go public at the Nasdaq, with the goal of raising […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

week 35 samsung google fda

News and Trends 27 Aug 2015

The 5 things outside Europe you need to know this week (Samsung $1Bn Biotech IPO, Microbiome blindness, Google Biotech)

Hi there! Here are the 5 most important Biotech things that happened outside Europe in the last few days. Enjoy and share! Samsung, Biogen lining up a $1B IPO for biosimilar joint venture: WSJ Samsung is also interested in Biotech and more precisely in Biosimilars. It created a joint-venture with Biogen and now wants to […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

oncodrone europe 2.5

News and Trends 27 Aug 2015

Dutch Startup receives €2.5M from Europe to Block Cancer’s Spreading

The Eurostars program supports the Dutch start-up Oncodrone with fresh money to bring its metastasis-blocking drug towards clinical trials. Even with a promising technology, it’s not easy to succeed in the biotech field. The Eurostars program helps small companies through the tough starting phase. This year, the 2013 founded biotech start-up Oncodrone gets a 2.5 […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

ADVERTISEMENT

News and Trends 26 Aug 2015

It’s proven: The (Almost) Universal Flu Vaccine is Possible!

The foundation stone was laid: A Dutch-American collaboration published in Science the first proof of concept that we could replace the seasonal flu shots with a vaccine that recognizes almost every subtype. The influenza virus is incredibly variable. A yearly refreshment of flu shots is necessary to provide a moderate protection against it, and subtypes […]

August 26, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 26 Aug 2015

Oh dear, Allergan is doing its 4th product recall in 2015 …

Allergan is fighting with manufacturing problems – again! The packaging of some eye treating products were defective and contaminated the eye ointments. Due to safety concerns, these products are recalled by the Irish company. Customers were complaining that when unscrewing the cap from the aluminum tube of the eye oinments, particles from the cap were […]

August 26, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 26 Aug 2015

Ouch! Novo Nordisk fails in Phase III

Novo Nordisk joins UCB and gets knocked down by its drug’s final clinical trial. Liraglutide, the already approved adjunct therapy for people with type 2 diabetes won’t reach out to type 1 diabetes. Novo Nordisk can look at a 90-year long history of improving the lives of diabetes patients. However, the phase IIIa trial that […]

August 26, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 25 Aug 2015

Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies

Two German biotechs with highly successful platforms join forces to fight cancer. MorphoSys and Immatics Biotechnologies want to generate novel antibody-based therapeutics against multiple cancer antigens. They are two of the thriving forces in the German biotech scene. Munich’s MorphoSys claims having developed the most successful antibody library technology in the pharma industry, currently has 100 […]

August 25, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 24 Aug 2015

Monoclonal Antibodies celebrate their 40th birthday, how were they discovered and changed the world?

It’s been 40 years now since the first monoclonal antibodies have been manufactured by researchers from UK’s Medical Research Council (MRC). Let’s go back to the beginning and see how they became global blockbusters. One cannot imagine today’s medical portfolio without monoclonal antibodies. Checkpoint therapies against cancer, immunosuppressives treating multiple sclerosis, vaccines against everything … […]

August 24, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 24 Aug 2015

Novartis signs $1Bn deal for GSK’s Multiple Sclerosis Antibody

Is this Novartis‘ next blockbuster? The Swiss company has acquired GlaxoSmithKline‘s (GSK) immunosuppressive antibody Ofatumumab for up to $1Bn. The new drug allows Novartis to enter the multiple sclerosis market for the third time. Earlier this year, Novartis purchased GSK’s oncology portfolio for $16 billion (€14Bn), including the fully human monoclonal anitbody Ofatumumab, which is […]

August 24, 2015 - 2 minutesmins - By Philip Hemme

ADVERTISEMENT